Endo International (ENDP) Has Catalysts Despite NT Weakness - Guggenheim
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Oppenheimer Remains Sidelined as Endo Int'l (ENDP) Shares Trade Down
March 21, 2016 10:08 AM EDTOppenheimer reiterated a Perform rating on Endo International plc (NASDAQ: ENDP) as shares trade down following Valeant's announcement that it was reducing its guidance. Endo management also announced a 1Q16 guidance revision. Management slightly decreased 1Q revenue guidance to ~21-22% of FY16 total revenues, and outlined sales of ~$928-$972M (vs. prior ~22% of... More
Endo Int'l (ENDP), Horizon (HZNP), Mallinckrodt (MNK) on Watch with Valeant (VRX) Halted
March 21, 2016 8:30 AM EDTEndo Int'l (NASDAQ: ENDP), Horizon Pharma (NASDAQ: HZNP) and Mallinckrodt (NYSE: MNK) are on watch with Valeant halted, news pending
UPDATE: Endo (ENDP) Downgraded From Top Pick to Outperform at RBC Following Recent Update
March 18, 2016 6:38 AM EDT(Updated - March 18, 2016 8:37 AM EDT)
RBC Capital downgraded Endo International plc (NASDAQ: ENDP) from Top Pick to Outperform with a price target of $47.00 (from $73.00). Analyst Randall Stanicky noted that shares are down 29% due to a sector pull-back tied to Valeant Pharma's sell-off. Endo also recently... More
